Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives

Experts examine recent updates in diffuse large B-cell lymphoma (DLBCL) treatment and explore practical strategies for implementing chimeric antigen receptor (CAR) T-cell therapy through academic and community collaboration.

Support provided in part by Kite. Content independently developed by OncLive.

EP. 1: Integrating CAR T-Cell Therapy Into the Treatment Landscape for R/R DLBCL

March 27th 2025

Experts discuss the role of chimeric antigen receptor T-cell therapy (CAR T) in the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), how they sequence between bispecific antibodies and CAR T, the frequency and patient selection for CAR T in the second-line setting, and key takeaways from a recent oral presentation on real-world outcomes with axicabtagene ciloleucel (axi-cel) in the second-line setting from ASH 2024.

EP. 2: Bispecific Antibodies vs CAR T-Cell Therapy: Treatment Selection and Sequencing in Later-Line R/R DLBCL

March 27th 2025

Experts discuss how they sequence bispecifics and other available therapies in the third-line setting and beyond for patients who did not receive chimeric antigen receptor T-cell therapy (CAR T) in the second-line setting, and whether their approach changes for those who have or have not received prior auto-transplant.

EP. 3: Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations

April 3rd 2025

Experts discuss the patient factors and disease characteristics that influence the selection of chimeric antigen receptor T-cell therapy (CAR T) options, how to determine if a patient is an appropriate candidate, and when to begin considering CAR T in the treatment journey.

EP. 4: Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL

April 3rd 2025

Experts discuss what they share with patients when counseling about the benefits and risks of chimeric antigen receptor T-cell therapy (CAR T).

EP. 5: Practical Realities of CAR T-Cell Therapy for R/R DLBCL: Challenges and Lessons From the Community

April 10th 2025

Experts discuss the main operational challenges faced in the community setting when it comes to chimeric antigen receptor T-cell therapy (CAR T) and the best practices implemented to mitigate these challenges.

EP. 6: Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients

April 10th 2025

Experts discuss when a patient should be referred from community practice to an academic or specialized program, the factors influencing the choice and timing of bridging therapy before CAR T infusion, and how bridging therapy is coordinated between academic and community settings.

x